Runwise ranks biotech and life science tools stocks on three things: money in the bank, strength of the pipeline, and where the industry is heading. It is a student research project.
Clinics and investors look at the same company with different goals. Runwise tries to respect both.
They ask if a study can be run safely and finished.
They ask if the company can earn a return.
Both sides care about cash runway and pipeline depth. A clinic does not want a sponsor that runs dry mid trial. An investor does not want to be diluted. That overlap is why those two ideas carry most of the weight in this model.
Each pillar is scored 0 to 100. The final score is a weighted average. Higher means lower risk.
runway = cash / (quarterly burn / 3)
Score = runway divided by 36 months, capped at 100. Burn uses operating cash use where found. Beam uses net loss as a proxy.
Stage 1 to 5 (50%), number of programs (20%), platform and team rating (30%).
A 1 to 10 judgment of demand and funding trends for the company's market, times 10.
Weights rescale to 100% and the ranking updates.
Scores compare the selected companies to each other. They are not absolute grades.
Enter figures from the company's latest filing, in $ millions. Burn is operating cash used per quarter. Type a ticker and press Look up to fill the name, cash, and burn from the latest SEC filing. Then set the four judgment fields yourself. Added companies are saved in this browser only.
Dark to light segments: financial, pipeline, industry. Each shows its weighted contribution.
Runway estimates use the same cash and burn inputs as the scoreboard.
Capex is money spent on equipment and buildings. For a biotech it shows how much cash goes into physical capacity instead of research. Heavy capex can shorten runway fast. Low capex can mean a lean lab or a company that outsources.
| Company | Capex found | What it suggests |
|---|---|---|
| Nautilus (NAUT) | About $1.3M in FY2025. Gross property and equipment rose about $1.1M in H1 2026 (from $11.6M to $12.7M). | Very light. Under 3% of yearly cash use. The cash goes to R&D, not buildings. |
| Quantum-Si (QSI) | $0.3M in Q1 2026. | Light, but it plans inventory investments ahead of the Proteus launch. |
| Recursion (RXRX) | Not included. | Capex was not part of the figures reviewed for this company. |
| Beam (BEAM) | Not included. | Beam says it is building internal manufacturing, so capex is a key number to watch. |